SCHEMBL1872883

SCHEMBL1872883

c1ccc(CN2CCC(N(CCc3ccccn3)Cc3cccc(CNCc4ccccn4)c3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ CXCR4 P61073 2/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ RAB9A P51151 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ PGR P06401 1/20 0.38
▸ BCHE P06276 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ ACKR3 P25106 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ DRD4 P21917 1/20 0.37
▸ DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29823986 1.00 MEN1 (0.41) MEN1KMT2AALDH1A1CXCR4SIGMAR1
SCHEMBL29823258 0.92 ALDH1A1 (0.43) MEN1KMT2AALDH1A1CXCR4SIGMAR1
SCHEMBL1877208 0.92 ALDH1A1 (0.43) MEN1KMT2AALDH1A1CXCR4SIGMAR1
SCHEMBL29823344 0.87 CXCR4 (0.51) MEN1KMT2AALDH1A1CXCR4SIGMAR1
SCHEMBL1879660 0.87 CXCR4 (0.51) MEN1KMT2AALDH1A1CXCR4SIGMAR1
SCHEMBL5790256 0.85 KMT2A (0.41) MEN1KMT2AALDH1A1CXCR4RAB9A
SCHEMBL1873995 0.84 KMT2A (0.50) MEN1KMT2AALDH1A1RAB9AL3MBTL1
SCHEMBL29823211 0.84 KMT2A (0.50) MEN1KMT2AALDH1A1RAB9AL3MBTL1
SCHEMBL29823432 0.84 CXCR4 (0.49) CXCR4SIGMAR1BCHECYP2D6CYP3A4
SCHEMBL1877188 0.84 CXCR4 (0.49) CXCR4SIGMAR1BCHECYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371361-A1 Methods to mobilize progenitor/stem cells Genzyme Global S.à.r.l. (LU) 2011-10-05 — — EP claimed
US-7935692-B2 Methods to mobilize progenitor/stem cells GENZYME CORPORATION (US) 2011-05-03 — — US claimed
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2010-04-29 — — US claimed
US-20100035941-A1 METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION GENZYME CORPORATION 2010-02-11 — — US claimed
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds ANORMED INC. (CA) 2006-11-23 — — US claimed
EP-1163238-B1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-05-31 — — EP claimed
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-25 — — US claimed
US-20250295698-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS ENSOMA INC (US) 2025-09-25 — — US disclosed
US-20250032549-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS ENSOMA INC (US) 2025-01-30 — — US disclosed
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION KEEFER, Edward (US) 2024-08-29 — — US disclosed
US-20240189387-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS ENSOMA, INC. 2024-06-13 — — US disclosed
EP-3735412-B1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS EDIGENE BIOTECHNOLOGY INC (CN) 2024-02-21 — — EP disclosed
EP-4308694-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS Magenta Therapeutics, Inc. (US) 2024-01-24 — — EP disclosed
EP-1163238-B1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-05-31 — — EP disclosed
US-20060035829-A1 Chemokine combinations to mobilize progenitor/stem cells ANORMED INC. 2006-02-16 — — US disclosed
US-6987102-B2 Methods to mobilize progenitor/stem cells ANORMED, INC. (CA) 2006-01-17 — — US disclosed
US-20050043367-A1 Methods to mobilize progenitor/stem cells ANORMED CORPORATION (CA) 2005-02-24 — — US disclosed
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-25 — — US disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 — — US disclosed
US-20030130250-A1 Methods to mobilize progenitor/stem cells ANORMED, INC. (CA) 2003-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 MEN1 4013/4885KMT2A 4150/4885ALDH1A1 1458/4885
US-20240189387-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS CXCL12, MCL1, MYADM MEN1 70/4885KMT2A 1317/4885ALDH1A1 1130/4885
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS CXCR4, CCR5, CXCR3 MEN1 4693/4885KMT2A 4681/4885ALDH1A1 2412/4885
US-20050043367-A1 Methods to mobilize progenitor/stem cells CXCL12, CXCR4, CXCR1 MEN1 4770/4885KMT2A 1572/4885ALDH1A1 110/4885
US-20060035829-A1 Chemokine combinations to mobilize progenitor/stem cells CXCL12, CXCR2, CXCR4 MEN1 4696/4885KMT2A 4537/4885ALDH1A1 328/4885
US-20100035941-A1 METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION CCR2, CXCR4, CXCR2 MEN1 4046/4885KMT2A 1732/4885ALDH1A1 784/4885
US-20250032549-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS CXCL12, CD44, CD47 MEN1 1187/4885KMT2A 1455/4885ALDH1A1 353/4885
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION CXCR3, CXCL12, CXCR4 MEN1 4348/4885KMT2A 3729/4885ALDH1A1 2426/4885
US-20030130250-A1 Methods to mobilize progenitor/stem cells CXCR4, CXCL12, CXCR2 MEN1 3350/4885KMT2A 1274/4885ALDH1A1 301/4885
US-20250295698-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS CXCL12, CSF3R, THPO MEN1 185/4885KMT2A 1994/4885ALDH1A1 671/4885
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 MEN1 4366/4885KMT2A 4002/4885ALDH1A1 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback